Mechanisms Mediating Osteoarthritis in Aging (R01) | Apply Online

Frequently Asked Questions (FAQs): Mechanisms Mediating Osteoarthritis in Aging (R01) (PA 16-239)

1) What is the title and identifier of this NIH funding opportunity?

The funding opportunity is titled "Mechanisms Mediating Osteoarthritis in Aging (R01)" and is identified as PA 16-239.

2) What is the main purpose of this funding opportunity?

The purpose is to support research that clarifies how osteoarthritis (OA) begins and worsens over time, with a specific emphasis on how aging influences OA initiation and progression.

3) What kind of research is NIH trying to encourage through this announcement?

This announcement encourages mechanistic, hypothesis-driven research that moves beyond broad or purely descriptive observations and instead develops testable explanations for OA disease initiation and progression in the context of aging-related biological changes.

4) What does "mechanisms mediating osteoarthritis in aging" mean in practical terms?

It refers to identifying and testing causal pathways, mediators, and biological interactions that explain why OA emerges and progresses, and specifically how aging changes risk, severity, or tissue responses over time.

5) What grant mechanism does this opportunity use?

This opportunity uses the NIH R01 mechanism, which is intended for substantive research projects with clearly defined aims, strong scientific rationale, and rigorous methods.

6) What types of projects are a good fit for an R01 under this FOA?

Projects are expected to be hypothesis-driven and to include clearly defined aims, a strong rationale, and rigorous methods aimed at producing mechanistic insights into OA initiation and progression as influenced by aging.

7) Is the focus on osteoarthritis generally, or specifically on osteoarthritis in aging?

The focus is specifically on osteoarthritis in the context of aging, emphasizing how age-related biological changes affect OA onset, progression, severity, and tissue or cellular responses.

8) Does the FOA emphasize descriptive studies, or mechanistic and causal studies?

The FOA emphasizes mechanistic and causal studies. Projects are expected to go beyond descriptive findings by identifying and testing causal pathways and mediators that explain disease development and progression.

9) What role do models play in this funding opportunity?

Models are central to this FOA. It is designed to encourage investigators to develop, refine, or more fully characterize new or underused experimental and analytical models of OA, and then use those models to test meaningful hypotheses about OA mechanisms in aging.

10) What does NIH mean by "new or underused" models in this context?

Based on the summary, this refers to experimental or analytical approaches that are not yet widely adopted in the field but could be especially informative for understanding aging-related OA mechanisms, particularly if they improve biological relevance to older organisms or better capture age-associated tissue and cellular changes.

11) What kinds of improvements to OA models are highlighted as important?

The summary highlights improvements such as making models more relevant to older organisms, capturing age-associated tissue and cellular changes, and reflecting the complex environment in which OA develops over years rather than weeks.

12) Is this opportunity intended to accelerate discovery in OA research?

Yes. The FOA is positioned to accelerate discovery by making it easier for researchers to pursue models that may not yet be widely adopted but could provide strong insights into aging-related OA mechanisms.

13) Which federal agency administers this grant opportunity?

This is a discretionary health research grant administered by the U.S. Department of Health and Human Services through the National Institutes of Health (HHS-NIH11).

14) What is the funding activity area for this opportunity?

The funding activity area is categorized under health.

15) What CFDA number(s) are associated with this funding opportunity?

The opportunity is associated with CFDA 93.866 (and references 93.866 in the provided summary).

16) Who is eligible to apply?

A broad range of applicants are eligible, including:

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and state-controlled institutions of higher education
• Private institutions of higher education
• Federally recognized Native American tribal governments
• Other tribal organizations
• Public housing authorities/Indian housing authorities
• Nonprofit organizations with 501(c)(3) status
• Nonprofit organizations without 501(c)(3) status
• For-profit organizations (other than small businesses)
• Small businesses
• Other eligible entities as described in the full announcement text

17) Does the eligibility list suggest NIH is limiting applications to universities only?

No. The eligibility list is broad and includes many organization types beyond universities, indicating NIH is open to proposals from many research-performing organizations that can meet NIH R01 scientific and administrative requirements.

18) When was this FOA created and posted?

The FOA was created and posted on May 9, 2016.

19) What is the listed closing date for the referenced cycle?

The listed closing date for the referenced cycle was September 7, 2019.

20) Does the provided summary specify an award ceiling?

No. The provided summary does not specify an award ceiling.

21) Does the provided summary specify the expected number of awards?

No. The provided summary does not specify the expected number of awards, which is described as common for certain NIH program announcements where awards depend on scientific merit, program priorities, and available funds rather than a fixed number.

22) What is the expected scientific direction or impact of projects funded under this FOA?

The expected direction is to strengthen the scientific foundation for understanding osteoarthritis as a disease strongly shaped by aging biology by promoting innovative or underutilized models and rigorous hypothesis testing aimed at explaining the mechanisms that trigger OA and drive its progression over time.

23) Are projects expected to address both OA initiation and progression?

Yes. The summary states the goal is to clarify how OA starts and how it worsens over time, emphasizing both initiation and progression, especially as influenced by aging.

24) What is the central aim of the announcement?

The central aim is to push the field beyond broad descriptions of OA and toward mechanistic, testable explanations of disease initiation and progression, particularly in the context of age-related biological changes.

25) What does the FOA imply about the time course OA models should reflect?

The FOA notes the value of models that better reflect the complex environment in which OA develops over years rather than weeks, implying an interest in approaches that capture longer-term, age-related disease dynamics.